Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T-Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s).

Next Previous
X
Search
Trial Profile

A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-T-Lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Lung transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Neovii Biotech

    • Most Recent Events

    • 10 Apr 2014 Results presented at the 34th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
    • 07 Jun 2012 Actual patient number changed from 222 to 223 as reported by ClinicalTrials.gov.
    • 15 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top